Cargando…

A Randomized, Placebo‐Controlled Phase III Extension Trial of the Long‐Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus

OBJECTIVE: To explore long‐term safety and tolerability of anifrolumab 300 mg compared with placebo in patients with systemic lupus erythematosus (SLE) who completed a Treatment of Uncontrolled Lupus via the Interferon Pathway (TULIP) trial and enrolled in the placebo‐controlled 3‐year long‐term ext...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kalunian, Kenneth C., Furie, Richard, Morand, Eric F., Bruce, Ian N., Manzi, Susan, Tanaka, Yoshiya, Winthrop, Kevin, Hupka, Ihor, Zhang, Lijin (Jinny), Werther, Shanti, Abreu, Gabriel, Hultquist, Micki, Tummala, Raj, Lindholm, Catharina, Al‐Mossawi, Hussein
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wiley Periodicals, Inc. 2022
Materias:	Systemic Lupus Erythematosus
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10098934/ https://www.ncbi.nlm.nih.gov/pubmed/36369793 http://dx.doi.org/10.1002/art.42392

Ejemplares similares

Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials
por: Bruce, Ian N, et al.
Publicado: (2022)

Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus
por: Morand, Eric F, et al.
Publicado: (2023)

Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials
por: Vital, Edward M, et al.
Publicado: (2022)

Anifrolumab, an Anti–Interferon‐α Receptor Monoclonal Antibody, in Moderate‐to‐Severe Systemic Lupus Erythematosus
por: Furie, Richard, et al.
Publicado: (2017)

Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis
por: Jayne, David, et al.
Publicado: (2022)

Long‐Term Safety and Efficacy of Anifrolumab in Adults With Systemic Lupus Erythematosus: Results of a Phase II Open‐Label Extension Study
por: Chatham, W. Winn, et al.
Publicado: (2021)

What Does It Mean to Be a British Isles Lupus Assessment Group–Based Composite Lupus Assessment Responder? Post Hoc Analysis of Two Phase III Trials
por: Furie, Richard, et al.
Publicado: (2021)

Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus
por: van Vollenhoven, Ronald F, et al.
Publicado: (2022)

Complement Activation in Patients With Probable Systemic Lupus Erythematosus and Ability to Predict Progression to American College of Rheumatology–Classified Systemic Lupus Erythematosus
por: Ramsey‐Goldman, Rosalind, et al.
Publicado: (2019)

Study of Flare Assessment in Systemic Lupus Erythematosus Based on Paper Patients
por: Isenberg, D., et al.
Publicado: (2017)

Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus
por: Urowitz, Murray B., et al.
Publicado: (2022)

Long‐Term Safety and Efficacy of Belimumab in Patients With Systemic Lupus Erythematosus: A Continuation of a Seventy‐Six–Week Phase III Parent Study in the United States
por: Furie, Richard A., et al.
Publicado: (2018)

Biological impact of iberdomide in patients with active systemic lupus erythematosus
por: Lipsky, Peter E, et al.
Publicado: (2022)

Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study
por: Hanly, John G., et al.
Publicado: (2019)

Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus
por: Wallace, Daniel J., et al.
Publicado: (2019)

Sifalimumab, a Human Anti–Interferon-α Monoclonal Antibody, in Systemic Lupus Erythematosus: A Phase I Randomized, Controlled, Dose-Escalation Study: A Phase I Randomized, Controlled, Dose-Escalation Study
por: Petri, Michelle, et al.
Publicado: (2013)

Mechanism of action of baricitinib and identification of biomarkers and key immune pathways in patients with active systemic lupus erythematosus
por: Dörner, Thomas, et al.
Publicado: (2022)

Phase III/IV, Randomized, Fifty‐Two–Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus
por: Ginzler, Ellen, et al.
Publicado: (2021)

Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double‐Blind, Placebo‐Controlled Trial
por: Morand, Eric, et al.
Publicado: (2022)

Belimumab in systemic lupus erythematosus
por: Vilas-Boas, Andreia, et al.
Publicado: (2015)

Viewpoint on anifrolumab in patients with systemic lupus erythematosus and a high unmet need in clinical practice
por: Tanaka, Yoshiya
Publicado: (2023)

Anifrolumab in lupus nephritis: results from second-year extension of a randomised phase II trial
por: Jayne, David, et al.
Publicado: (2023)

Association of Systemic Lupus Erythematosus With Decreased Immunosuppressive Potential of the IgG Glycome
por: Vučković, Frano, et al.
Publicado: (2015)

Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double‐Blind, Placebo‐Controlled Trials
por: Clowse, Megan E. B., et al.
Publicado: (2017)

Transcriptome reprogramming and myeloid skewing in haematopoietic stem and progenitor cells in systemic lupus erythematosus
por: Grigoriou, Maria, et al.
Publicado: (2020)

Molecular pathways in patients with systemic lupus erythematosus revealed by gene-centred DNA sequencing
por: Sandling, Johanna K, et al.
Publicado: (2021)

3D genome alterations in T cells associated with disease activity of systemic lupus erythematosus
por: Zhao, Ming, et al.
Publicado: (2023)

Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study
por: Tian, Jingru, et al.
Publicado: (2023)

Sensitivity to Change and Minimal Important Differences of the LupusQoL in Patients With Systemic Lupus Erythematosus
por: McElhone, Kathleen, et al.
Publicado: (2016)

Altered cognitive function in systemic lupus erythematosus and associations with inflammation and functional and structural brain changes
por: Barraclough, Michelle, et al.
Publicado: (2019)

Long‐Term Clinical Outcomes in a Cohort of Adults With Childhood‐Onset Systemic Lupus Erythematosus
por: Groot, N., et al.
Publicado: (2019)

Pragmatic Treatment of Patients With Systemic Lupus Erythematosus With Rituximab: Long‐Term Effects on Serum Immunoglobulins
por: Reddy, Venkat, et al.
Publicado: (2017)

Meta-analysis of 208370 East Asians identifies 113 susceptibility loci for systemic lupus erythematosus
por: Yin, Xianyong, et al.
Publicado: (2021)

Low-density granulocytes activate T cells and demonstrate a non-suppressive role in systemic lupus erythematosus
por: Rahman, Saifur, et al.
Publicado: (2019)

Dynamics of Methylation of CpG Sites Associated With Systemic Lupus Erythematosus Subtypes in a Longitudinal Cohort
por: Lanata, Cristina M., et al.
Publicado: (2022)

Biological insights into systemic lupus erythematosus through an immune cell-specific transcriptome-wide association study
por: Yin, Xianyong, et al.
Publicado: (2022)

Efficacy and Safety of Subcutaneous Belimumab in Anti–Double‐Stranded DNA–Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus
por: Doria, A., et al.
Publicado: (2018)

Metagenome-wide association study revealed disease-specific landscape of the gut microbiome of systemic lupus erythematosus in Japanese
por: Tomofuji, Yoshihiko, et al.
Publicado: (2021)

Predictors of Unsuccessful Hydroxychloroquine Tapering and Discontinuation: Can We Personalize Decision‐Making in Systemic Lupus Erythematosus Treatment?
por: Almeida‐Brasil, Celline C., et al.
Publicado: (2022)

Peroxisome proliferator activated receptor-γ agonist pioglitazone improves vascular and metabolic dysfunction in systemic lupus erythematosus
por: Hasni, Sarfaraz, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_od8k80foao1r9ji351ngllnaap